Simulation-based Bayesian predictive probability of success for interim monitoring of clinical trials with competing event data: two case studies Publication type: Research Article Journal: Journal Volume: 00

Chiara Micoli, Alessio Crippa, Jason T. Connor, I-SPY COVID Consortium, Martin Eklund, Andrea Discacciati · 2024

Read Simulation-based Bayesian predictive probability of success for interim monitoring of clinical trials with competing event data: two case studies Publication type: Research Article Journal: Journal Volume: 00 by Chiara Micoli, Alessio Crippa, Jason T. Connor, I-SPY COVID Consortium, Martin Eklund, Andrea Discacciati (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2412-15899.txt.

Introduction

Half-way through a trial, sponsors ask the only question that counts: will it win? Chiara Micoli and co-authors compute that chance in 2024 for trials where patients can meet rival ends — heal, worsen, or die — and only one can come first. No set method existed for that tangle.

Their route simulates the rest of the trial, again and again, from hazard models for each rival end. Each run's win is scored at fixed settings, then averaged over what the data so far support. Two real trials ground the work, one of them a COVID ward study. The chance score can steer a trial's size, or end a hopeless one early. Simulation does the heavy lift throughout.

Catalog record

CREATORChiara Micoli, Alessio Crippa, Jason T. Connor, I-SPY COVID Consortium, Martin Eklund, Andrea Discacciati
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE47 KB
VERSION1.0
LICENSEhttp://creativecommons.org/licenses/by/4.0/
RIGHTSCC BY
SOURCEarXiv

Source: https://arxiv.org/abs/2412-15899

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Simulation-based Bayesian predictive probability of success for interim monitoring of clinical trials with competing event data: two case studies Publication type: Research Article Journal: Journal Volume: 00 Chiara Micoli, Alessio Crippa, Jason T. Connor, I-SPY COVID Consortium, Martin Eklund, Andrea Discacciati Abstract Bayesian predictive probabilities of success (PPoS) use interim trial data to calculate the probability of trial success. These quantities can be used to optimize trial size or to stop for futility. In this paper, we describe a simulation-based approach to compute the PPoS for clinical trials with competing event data, for which no specific methodology is currently available. The proposed procedure hinges on modelling the joint distribution of time to event and event type by specifying Bayesian models for the cause-specific hazards of all event types. This allows the prediction of outcome data at the conclusion of the trial. The PPoS is obtained by numerically averaging the probability of success evaluated at fixed parameter values over the posterior distribution of the parameters. Our work is motivated by two randomised clinical trials: the I-SPY COVID phase II trial for the treatment of severe COVID-19 (NCT04488081) and the STHLM3 prostate cancer diagnostic trial (ISRCTN84445406), both of which are characterised by competing event data. We present different modelling alternatives for the joint distribution of time to event and event type and show how the choice of the prior distributions can be used to assess the PPoS under different scenarios. The role of the PPoS analyses in the decision making process for these two trials is also discussed. keywords Bayesian predictive probability of success, competing events, interim analysis, clinical trials \copyyear 2024 \startpage 1 \authormark MICOLI et al. \titlemark Predictive probability of success with competing event data \corres Chiara Micoli, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, PO Box 281, SE-17177 Stockholm, Sweden. † † footnotetext: Abbreviations: DMC, data monitoring committee; HR, hazard ratio; PCa, prostate cancer; PCM, prostate cancer mortality; PCH, piecewise constant cause-specific hazard; PPoS, predictive probability of success; PSA, prostate-specific antigen; RR, risk ratio. 1 Introduction The interim monitoring of clinical trials has become an essential component of trial design 1 . Bayesian methods are particularly well suited for this purpose, as they enable the prediction of the probability of trial success at its conclusion based on interim data, averaged over the posterior distribution of the treatment effect and other nuisance parameters 2 . By predicting the probability that the trial will provide sufficient evidence to support the study’s primary hypothesis if the trial continues to its end, the Bayesian predictive probability of success (PPoS) can inform decisions regarding the continuation, modification, or early termination of the trial. If the PPoS is too low, and the trial is therefore predicted to be unlikely to achieve its objective, the trial may be stopped early for futility 3 , 4 , reducing the risk of exposing patients to ineffective or harmful therapies and conserving resources that can be reallocated to more promising trials 1 . Conversely, if completing the prespecified follow-up period for patients who have already been enrolled is predicted to lead to success with a sufficiently high probability, enrollment of new patients can be stopped, and the primary outcome can be analysed at the conclusion of the follow-up period 3 , 5 . Furthermore, the PPoS can be employed to adjust the sample size at interim analyses 6 or to inform the timing of the primary analysis, by determining the minimum duration of the follow-up period required to achieve a certain PPoS 7 . The PPoS has been primarily employed to monitor clinical trials with continuous or binary endpoints, e.g. in the I-SPY 2 trial 8 and the REST trial 9 . The use of PPoS in clinical trials with survival data is less common 10 , 11 and the existing methodology is limited to the setting where the endpoint is the time span from some time origin (e.g. randomisation) until the occurrence of one single type of event 6 , 11 , 12 , 13 , 14 , 15 . Competing events occur frequently in survival data from clinical trials, where patients may experience different types of events and the occurrence of one event precludes the occurrence of all other event types 16 . For example, in randomised clinical trials evaluating potential treatments for hospitalised patients diagnosed with COVID-19, hospital discharge due to recovery and death without prior recovery are mutually exclusive (i.e. competing) events 17 . To fill this gap, in this paper we take the approach of computing PPoS using statistical simulation 18 and extend it to the setting of survival data with competing events. We propose to model the joint distribution of time to event and event type by specifying Bayesian models for the cause-specific hazard functions, allowing the prediction of the outcome data at the conclusion of the trial and thus the computation of the PPoS. Our suggested procedure provides a general approach that can be used for interim monitoring of newly designed trials or to extend existing designs, for example for phase II 19 or phase III clinical trials 6 , to competing event data. Our work is motivated by two randomised clinical trials: the I-SPY COVID phase II trial for the treatment of severe COVID-19 20 (NCT04488081) and the STHLM3 prostate cancer diagnostic trial 21 (ISRCTN84445406). Both trials are characterised by a time-to-event outcome, namely time to recovery from COVID and time to prostate cancer mortality. In the I-SPY COVID trial, death from any cause is a competing event and the PPoS was used at interim monitoring to inform the decision to continue randomisation of patients to a specific investigational agent. In the STHLM3 trial, death from causes other than prostate cancer is a competing event and the PPoS was employed to predict the shortest follow-up period necessary to accumulate enough prostate cancer deaths in order to reach sufficient power for the final analysis. 2 Methods 2.1 Notation and preliminaries For each subject s , where s=1,\ldots,S , let T_{s} be the an absolutely continuous variable representing the true event time with support on the positive real half-line, and let X_{s}\in\{1,\ldots,I\} be the competing event indicator. The right-censored event time is denoted by Y_{s}=\min(T_{s},C_{s}) , where C_{s} is the censoring time (generally assumed independent of T_{s} and X_{s} ), and \Delta_{s}=\mathbbm{1}(T_{s}\leq C_{s})\cdot X_{s}\in\{0,1,\ldots,I\} is the observed event indicator, where 0 indicates right censoring. The pair ( Y_{s} , \Delta_{s} ) defines the right-censored outcome data. Lastly, let Z_{s} be a vector of baseline covariates, including at least the randomisation arm A_{s} . In total, we define the random vector D_{s}=(Y_{s},\Delta_{s},Z_{s}) . Hereafter, we suppress the subscript s to simplify notation. The cause-specific hazard for the i -th competing event is defined as \lambda_{i}(t)=\lim_{dt\downarrow 0}\frac{\Pr(T\leq t+dt,X=i\,|\,T>t)}{dt}. The cause-specific hazards for all events collectively define the joint distribution of (T,X) 22 . The crude cumulative probabilities (risks) of experiencing the competing event i by the time t are defined as F_{i}(t)=\Pr(T\leq t,X=i)=\int_{0}^{t}\lambda_{i}(u)S(u)du , where S(t)=\Pr(T>t)=\exp(-\sum_{i=1}^{I}\int_{0}^{t}\lambda_{i}(u)du) is the event-free survival function. The cause-specific hazards and the crude cumulative risks are not only two possible quantities that define the joint distribution of (T,X) , but they are also quantities of scientific interest in clinical research

Read the complete text